These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
333 related articles for article (PubMed ID: 11147391)
1. Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice. Mauskopf JA; Richter A; Annemans L; Maclaine G Pharmacoeconomics; 2000 Sep; 18(3):239-51. PubMed ID: 11147391 [TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation. Legendre C; Beard SM; Crochard A; Lebranchu Y; Pouteil-Noble C; Richter A; Durand-Zaleski I Eur J Health Econ; 2005 Jun; 6(2):172-82. PubMed ID: 15765243 [TBL] [Abstract][Full Text] [Related]
3. A decision-analytic economic evaluation of valaciclovir prophylaxis for the prevention of cytomegalovirus infection and disease in renal transplantation. Tilden DP; Chapman J; Davey PJ; Solly ML; Crowley S Clin Transplant; 2004 Jun; 18(3):312-20. PubMed ID: 15142054 [TBL] [Abstract][Full Text] [Related]
4. Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation. Legendre CM; Norman DJ; Keating MR; Maclaine GD; Grant DM Transplantation; 2000 Nov; 70(10):1463-8. PubMed ID: 11118091 [TBL] [Abstract][Full Text] [Related]
5. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408 [TBL] [Abstract][Full Text] [Related]
6. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989 [TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients. Kielberger L; Bouda M; Jindra P; Reischig T Kidney Blood Press Res; 2012; 35(6):407-16. PubMed ID: 22584353 [TBL] [Abstract][Full Text] [Related]
8. The efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation. Reischig T; Kacer M Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):771-9. PubMed ID: 25252996 [TBL] [Abstract][Full Text] [Related]
9. The economic value of valacyclovir prophylaxis in transplantation. Squifflet JP; Legendre C J Infect Dis; 2002 Oct; 186 Suppl 1():S116-22. PubMed ID: 12353196 [TBL] [Abstract][Full Text] [Related]
10. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Hodson EM; Ladhani M; Webster AC; Strippoli GF; Craig JC Cochrane Database Syst Rev; 2013 Feb; (2):CD003774. PubMed ID: 23450543 [TBL] [Abstract][Full Text] [Related]
11. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective. Kacer M; Kielberger L; Bouda M; Reischig T Transpl Infect Dis; 2015 Jun; 17(3):334-41. PubMed ID: 25824586 [TBL] [Abstract][Full Text] [Related]
12. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Reischig T; Jindra P; Hes O; Svecová M; Klaboch J; Treska V Am J Transplant; 2008 Jan; 8(1):69-77. PubMed ID: 17973956 [TBL] [Abstract][Full Text] [Related]
13. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease]. Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888 [TBL] [Abstract][Full Text] [Related]
14. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085 [TBL] [Abstract][Full Text] [Related]
16. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021 [TBL] [Abstract][Full Text] [Related]
17. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections. Ormrod D; Scott LJ; Perry CM Drugs; 2000 Apr; 59(4):839-63. PubMed ID: 10804039 [TBL] [Abstract][Full Text] [Related]
18. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Noble S; Faulds D Drugs; 1998 Jul; 56(1):115-46. PubMed ID: 9664203 [TBL] [Abstract][Full Text] [Related]
19. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients. Reischig T; Opatrný K; Treska V; Mares J; Jindra P; Svecová M Kidney Blood Press Res; 2005; 28(4):218-25. PubMed ID: 16043964 [TBL] [Abstract][Full Text] [Related]
20. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients. Oppenheimer F; Gonzalez-Molina M; Rubio M Clin Transplant; 2007; 21(4):441-8. PubMed ID: 17645702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]